Decision board
Advancements, growth, technology and impact
Morning briefing insights
Morning briefing
See the verified move that matters, the decision still in dispute, and the constraint that can still block adoption.
Start with the clearest verified move, the decision it could change, and the friction that could still slow real-world use.
Live briefing pulse
Prepared 1 July 2026
The latest edition and monthly headline context load here.
Shortcut rail
Fast routes into detail
Current edition
What does today’s archived state say?
Headlines of the month
What kept accumulating this month?
Trust logic
Why this briefing can be trusted fast
Primary-source first
Approvals, study results, and commercial facts stay anchored to official or peer-reviewed sources where verified.
Unknowns stay visible
Launch dates, India access, and pricing remain explicitly unverified when the evidence does not support a stronger claim.
Every week is retained
The current state is not disposable. Archived editions and monthly headlines preserve what was true on each dated pass.
Edition archive
Retain every verified weekly state as a dated newsletter, not a disappearing overwrite.
Reopen any dated edition, from June 15 through July 1, and see the summary, headlines, and spotlight items exactly as they appeared that week.
0newsletter editions
Monthly headlines plus dated weekly states
Monthly rollup
Headlines of the month
Weekly archive
Open a past newsletter edition
Selected edition
Weekly newsletter detail
Curated global portfolio
Search once, then read the verified oncology record without bouncing across the dashboard.
This page unifies the dashboard's treatment dossiers, ASCO follow-up programs, and watchlist/system signals into one searchable portfolio. It reuses only the verified fields already captured elsewhere in the product, so missing values remain explicitly labeled instead of inferred.
0verified records
Drug, company, program, or cancer type
Search results
Curated oncology records
Selected record
Verified detail
Curation method
Designed to stay rigorous
No new inference layer. The portfolio page does not invent labels, outcomes, prices, approvals, or launch dates; it only reorganizes already-verified dashboard records.
Cross-lane search. Treatments, regulatory follow-up programs, and system/watchlist signals are searchable from one place so users can find a molecule or issue without knowing the source section first.
Explicit uncertainty. Conference-only, investigational, negative, and region-divergent records keep their original caution labels rather than being flattened into a generic product card.
Route back to depth. Every result keeps a link back to its original treatment, follow-up, or watchlist dossier so the portfolio stays curated instead of bloated.
0 advances shown Select up to three for direct comparison.
Commercialization lens
India availability is indication-specific.
A product may be marketed in India while the ASCO study regimen remains off-label or investigational. Converted US prices are shown only as context and are not Indian market prices.
Illustrative conversion used
₹95.4 / US$
June 2026 reference
Access, price and launch
India commercialization tracker
Implementation gap
Operational performance vs clinical proof
Global oncology
Equity and system capacity
Brazil · prostate cancer
670,205
men treated in the public system; racial differences persisted in stage, local treatment and recorded expenditure.
Kyrgyzstan · cancer burden
+21.6%
increase in reported new cases from 2020 to 2024, increasing pressure on diagnostics and treatment capacity.
One year later · baseline 9 June 2026, refreshed for later milestones
Which ASCO 2025 signals actually moved forward?
This tracker shows which major ASCO 2025 regimens actually moved forward into practice, guidelines, review, or approval. A strong conference result stays provisional until a later milestone is verified.
0programs tracked
Selected, not exhaustive
Program register
Evidence, regulation and next catalyst
Conference-to-care narratives
What happened after the presentation?
What the year changed
Follow-through assessment
Method
How status was assigned
Approved means a regulator has authorized the ASCO regimen and population.
Under review means a formal application or positive committee opinion is verified, but final authorization may still be pending.
Guideline signal means clinical use may advance before a new label, but regulatory and reimbursement status can differ.
Ongoing development includes publication, follow-up or further trials without verified approval for the studied use.
Open-ended weekly review · updated 25 June 2026
Material developments that do not fit the treatment cards need their own lane.
This watchlist keeps conference signals, negative screening results, surgery-sparing approaches, and system-capacity warnings in view when they could change oncology decisions but still fall short of routine-care adoption.
0signals tracked
Conference-only and system-level items clearly labeled
Decision register
Why these signals matter even without a full product launch or new label
Dossiers